Navigation Links
Corgenix Reports Second Quarter Fiscal 2010 Financial Results
Date:2/11/2010

DENVER, Feb. 11 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its 2nd quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues slightly declined during the quarter but slightly increased for the six months ended December 31, 2009. Some of the results highlighted by the report are as follows:

  • Revenues for the quarter decreased $35,574 or 1.8% vs. the prior year's comparable quarter
  • Total operating expenses decreased $147,774 or 12.2% vs. the prior year's comparable quarter
  • Operating income for the quarter was $12,395 vs. an operating loss of $56,223 for the prior year's comparable quarter
  • Net loss decreased to $83,841 or 68.8% in the current quarter from $268,374 in the prior year's comparable quarter

Douglass Simpson, Corgenix CEO and President, stated, "Compared to the prior year, revenues softened slightly in the second quarter, largely due to a decrease in our private label (OEM) and contract manufacturing business sectors, partially offset by slight growth in our direct product sales. We have recently added new contract manufacturing customers and are continuing to focus on the expansion and strengthening of this segment of our business."

The company further noted that the financial performance for the quarter was not as strong as expected, with continued weakness in core product revenue. The company continues to remain hopeful that Fiscal Year 2010 revenues will exceed those of the prior fiscal year, even though there can be no assurance that this will be the case.

Second Quarter 2010 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of second quarter results to join a shareholders conference call on Thursday, February 11, 2010, at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 862-9098. International participants may access the call by dialing +1 785-424-1051. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 283-4641 for domestic participants and +1 402-220-0851 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

    
    
    
                           SUMMARY OF FINANCIAL HIGHLIGHTS
      ($000 of U.S. dollars except shares outstanding and per share amounts)
    
                    CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
                                   OPERATIONAL DATA
    
                       Three Months Ended              Six Months Ended
                       ------------------              ----------------
                  December 31,     December 31,   December 31,    December 31,
                       2009            2008           2009            2008
                   (unaudited)     (unaudited)    (unaudited)     (unaudited)
                   -----------     -----------    -----------     -----------
    Net sales          $1,959          $1,995         $4,004          $3,997
    Gross
     profit             1,075           1,154          2,191           2,261
    Total
     operating
     expenses           1,063           1,210          2,094           2,411
    Operating
     income
     (loss)                12             (56)            96            (150)
    Net loss              (84)           (268)           (91)           (609)
    Basic and
     diluted
     loss per
     share             $(0.00)         $(0.01)        $(0.00)         $(0.02)
    Diluted
     shares
     outstanding   31,033,209      30,280,155     30,669,532      30,186,124
    
     
    
    
                              SUMMARY BALANCE SHEET DATA
                                    (in thousands)
    
                                   December 31, 2009     June 30, 2009
                                      (unaudited)         (audited)
                                       ----------         ---------
    Cash                                   $662              $785
    Working capital                       2,043             2,013
    Total assets                          6,367             6,906
    Long-term debt                          607               744
    Total stockholders' equity            3,052             3,113
    
    

SOURCE Corgenix Medical Corporation

RELATED LINKS
http://www.corgenix.com

'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
2. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
3. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
4. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
5. Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced in February and ... WUGC is being held in London, England this year from June 18-25. At the last ... gold in the women’s masters division, and a silver in the women’s division, so Mazur ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... will be held at the Bellagio Hotel in Las Vegas, NV from October ... (NASW) will be co-hosting the event. , This year’s conference will offer ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t ... number five on the list of “ 5 US Cities with the Highest Plastic Rates ... Angeles, and Miami. The results were calculated using a survey by RealSelf ...
(Date:5/2/2016)... Ocean City, MD (PRWEB) , ... May 02, 2016 , ... ... high quality SUP boards at affordable prices announced today the outcome of their partnership ... what has been termed the “Roots Yoga Board.” , SUP yoga has seen a ...
(Date:5/2/2016)... ... May 02, 2016 , ... In response to recent growth and ... Low Vision and Blindness (NELV&B) , announces the opening of a new low vision ... with vision impairments to get assessments, hands-on experience and training with low vision and ...
Breaking Medicine News(10 mins):